5-Aminolevulinic acid a biomarker for worse prognosis in IDH-wildtype brain tumors? Evolution of a Fluorescence-Positive Diffuse Astrocytoma: Case Report
Introduction: In 2017, the U.S Food and Drug Administration (FDA) approved 5-Aminolevulinic Acid (5-ALA) as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs). However, the application of 5-ALA for low-grade gliomas is still less accepted. Case Report: A 74-year-old male patient was diagnosed with a right parietal lesion suggestive of a low-grade brain tumor in a surgical resection using 5-ALA, which led to the detection of tiny fluorescence spots during the surgery. The frozen section was consistent with Diffuse astrocytoma, IDH-wildtype (WHO grade II). The patient's postoperative MRI showed complete resection. Eight months after surgery, he began experiencing symptoms again and was admitted with a brain MRI finding consistent with recurrent infiltrating astrocytomas. This required reoperation of the brain tumor resection with 5-ALA. Unlike the first surgery, they observed a high fluorescence intensity; the pathological finding was Glioblastoma, IDH-wildtype (WHO Grade IV). Post-surgical brain MRI showed total resection of the tumor. The patient was discharged four weeks after surgery and continued with specialized clinical follow-up. Conclusion: The use of 5-ALA increasingly approaching its use as a prognostic tool for aggressive clinical behavior. This case report expand knowledge for potentially using to prognosticate IDH-wildtype II tumors.
- Weitere Titel
-
5Aminolevulinic acid biomarker for wildtype tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
5-Aminolevulinic acid a biomarker for worse prognosis in IDH-wildtype brain tumors? Evolution of a Fluorescence-Positive Diffuse Astrocytoma: Case Report ; day:22 ; month:05 ; year:2022
Journal of neurological surgery reports ; (22.05.2022)
- Beteiligte Personen und Organisationen
-
Valerio, Jose E.
Ochoa, Sebastian
Borro, Matteo
Alvarez, Sandra
ALVAREZ, ANDRES M.
- DOI
-
10.1055/a-1858-7628
- URN
-
urn:nbn:de:101:1-2022071410484857109566
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Valerio, Jose E.
- Ochoa, Sebastian
- Borro, Matteo
- Alvarez, Sandra
- ALVAREZ, ANDRES M.
Ähnliche Objekte (12)
Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Genetically engineered murine NSCs mimic human IDH-mut astrocytoma
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Methylation class oligosarcoma may encompass IDH-wildtype gliomas
FET-PET-based radiomics in IDH-wildtype glioblastoma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification
Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
Analyses of metastasis-associated genes in IDH wild-type glioma
Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Genetically engineered murine NSCs mimic human IDH-mut astrocytoma
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Methylation class oligosarcoma may encompass IDH-wildtype gliomas
FET-PET-based radiomics in IDH-wildtype glioblastoma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification
Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
Analyses of metastasis-associated genes in IDH wild-type glioma
Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Genetically engineered murine NSCs mimic human IDH-mut astrocytoma
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
Methylation class oligosarcoma may encompass IDH-wildtype gliomas
FET-PET-based radiomics in IDH-wildtype glioblastoma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification
Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma